

DON'T MISS THIS EXCITING OPPORTUNITY!

LONHALA™ MAGNAIR™

(glycopyrrolate) Inhalation Solution

The First and Only Nebulized LAMA for COPD
Including Chronic Bronchitis and/or Emphysema

Join your peers for an interactive program to:

- Explore the clinical efficacy and safety data of LONHALA MAGNAIR
- Learn the key device features of LONHALA MAGNAIR and receive instruction on how to properly administer LONHALA using the MAGNAIR Nebulizer System

COPD, chronic obstructive pulmonary disease; LAMA, long-acting muscarinic antagonist.

This promotional, non-CME program is intended only for US health care professionals involved in the treatment of patients with COPD.

Please see additional requirements regarding attendance at this program on the following page.

**Seating is limited,
so register now.**

Enter 70669 [here](#).



Registration is preferred.

Please note: This program is subject to cancellation. For additional program information, call (844) 620-8898 and reference the provided meeting code.

Indication

LONHALA™ MAGNAIR™ (glycopyrrolate) inhalation solution is an anticholinergic indicated for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

Please see the Important Safety Information below and the full Prescribing Information and Patient Information at www.SunovionProFile.com/LONHALA-MAGNAIR.

LONHALA and  are trademarks of Sunovion Pharmaceuticals Inc. MAGNAIR is a trademark of PARI Pharma GmbH, used under license. SUNOVION and  are registered trademarks of Sumitomo Dainippon Pharma Co., Ltd. Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of Sumitomo Dainippon Pharma Co., Ltd.

©2018 Sunovion Pharmaceuticals Inc. All rights reserved. 2/18 LON024-18

PROPERTY OF SUNOVION PHARMACEUTICALS INC. PROPRIETARY AND NONTRANSFERABLE. NOT FOR FURTHER DISSEMINATION.

EVENT DETAILS

Sunovion Representative

Cori Axe
Cori.Axe@sunovion.com
717-380-1888

Presented by:

Gaurav Patel, MD
Medical Director
Pulmonary, Critical Care and Sleep Center
Riddle Memorial Sleep Center
Media, PA

Saturday, November 10, 2018

6:30 AM

The Hotel Hershey

100 Hotel Road
Hershey, PA 17033
717-533-2171

Meeting Code: 70669

Attendees will have the option to accept the Sunovion-provided food and beverage service, opt out of all food and beverage, or purchase their own food and beverage.

There is no cost to attend this meeting.

 **Lonhala™ Magnair™**
(glycopyrrolate) Inhalation Solution
25 mcg/1 mL

This promotional non-CME program is sponsored by

 **sunovion**

Important Safety Information

LONHALA MAGNAIR is contraindicated in patients with a hypersensitivity to glycopyrrolate or to any of the ingredients.

LONHALA MAGNAIR should not be initiated in patients with acutely deteriorating or potentially life-threatening episodes of COPD or used as rescue therapy for acute episodes of bronchospasm. Acute symptoms should be treated with an inhaled short-acting beta₂-agonist.

As with other inhaled medicines, LONHALA MAGNAIR can produce paradoxical bronchospasm that may be life-threatening. If paradoxical bronchospasm occurs following dosing with LONHALA MAGNAIR, it should be treated immediately with an inhaled, short-acting bronchodilator; LONHALA MAGNAIR should be discontinued immediately and alternative therapy instituted.

Immediate hypersensitivity reactions have been reported with LONHALA MAGNAIR. If signs occur, discontinue LONHALA MAGNAIR immediately and institute alternative therapy.

LONHALA MAGNAIR should be used with caution in patients with narrow-angle glaucoma and in patients with urinary retention. Prescribers and patients should be alert for signs and symptoms of acute narrow-angle glaucoma (e.g., eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema) and of urinary retention (e.g., difficulty passing urine, painful urination), especially in patients with prostatic hyperplasia or bladder-neck obstruction. Patients should be instructed to consult a physician immediately should any of these signs or symptoms develop.

The most common adverse events reported in ≥2% of patients taking LONHALA MAGNAIR, and occurring more frequently than in patients taking placebo, were dyspnea (4.9% vs 3.0%) and urinary tract infection (2.1% vs 1.4%).

LONHALA solution is for oral inhalation only and should not be injected or swallowed. LONHALA vials should only be administered with MAGNAIR.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For additional information, please see and Patient Information at www.SunovionProFile.com/LONHALA-MAGNAIR.

Sunovion Pharmaceuticals Inc. is committed to the principles in the PhRMA Code on Interactions with Healthcare Professionals. This code helps to ensure that the highest professional and ethical standards are being met in the pharmaceutical industry. As part of our commitment to the PhRMA code, please note that attendance at this program is limited to health care professionals, and inclusion of spouses or other guests is not permitted.

Sunovion complies with all state and federal aggregate spend reporting laws that require the company to publicly disclose remuneration of identified health care professionals to government agencies.

Attention: all New Jersey licensed Prescribers (Physicians, Podiatrists, Physician Assistant, Advanced Practice Nurse, Dentist, and Optometrist) MUST identify yourself to the Therapeutic Specialist at the meeting. The meal associated with this event exceeds the \$15 meal cap. You may still attend this event and either opt-out of the meal provided or pay out of pocket for the meal.

Please see the most recent version of our privacy policy, which may change from time to time, at www.sunovionpolicies.com/privacy-policy.html. If you decide you no longer wish to receive communications from Sunovion, you may opt out at any time by notifying us at Sunovion Pharmaceuticals Inc., 84 Waterford Drive, Marlborough, MA 01752; at 1-888-394-7377; or at info@sunovion.com.

[Unsubscribe](#) | [Contact Us](#) | [Privacy Policy](#)

PLEASE DO NOT RESPOND TO THIS EMAIL AS IT IS NOT MONITORED.